Want to join the conversation?
$JNJ's Janssen Research & Development Phase 3 data presented for the first time at Digestive Disease Week 2016 showed that a significantly greater proportion of adult patients with moderate to severe Crohn's disease receiving STELARA (ustekinumab) subcutaneous (SC) maintenance therapy were in clinical remission at one year.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.